Standard Biotools Inc LAB

$0.69 +0.02 (2.85%)

Valuation

Market cap
270,644,000
Revenue TTM
$85,330,000
Net income TTM
$-74,900,000
PE ratio
0.00
Forward PE
—
Profit margin
-87.78%
Debt to equity
0.00

Trading

Volume
652,200
Avg volume
1,371,348
Day's range
$0.66 – $0.70
Shares out
392,579,000
Stochastic %K
31%
Beta
1.36
Analysts
Hold
Price target
$1.35

Price

Company profile

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for...

Show more

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Industry
Medical Devices
Sector
Healthcare
Phone
650 266 6000
Website
https://www.standardbio.com
Address
50 Milk Street, 10th Floor, Boston, United States

Latest news

Stocktwits

focafoca99 Oct 5, 8:28 PM
$LAB selling its Microfluidics business to ARCHIMED in a definitive agreement, closing expected in ~30 days.
1 replies
grnback Oct 3, 2:32 AM
0 replies
JudoFiah Sep 22, 4:00 PM 0 replies
JudoFiah Sep 12, 10:09 AM
$LAB when is the shareholder vote on the merger?
1 replies
web10x Sep 1, 9:07 AM
$BTR is making a comeback. 📈 Retail traders should watch closely. 🚨 Momentum is waking up again. 📈 Next move could surprise the market. 🔥 I’m watching $LAB as the next play. ⚠️ Don’t chase green candles blindly. 📉 Manage risk before entering. Could $LAB become the next $BTR? #tradingcommunity #altcoins
1 replies
WallStreetWoof Aug 26, 5:15 PM
$LAB Someone needs to feed this LAB some puppy chow with fortified vitamins and minerals
0 replies
goofyfoot Aug 25, 7:36 PM
$LAB Back in this at 64 cents. Eh, what can go wrong? 🤔😎
1 replies
SnowyDingo Aug 21, 1:57 PM
$LAB https://www.gurufocus.com/news/9046708/long-focus-capital-management-llc-adds-to-standard-biotools-inc-lab-stake-shares-look-11-undervalued-on-gf-value
0 replies